Sacituzumab govitecan: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Sacituzumab govitecan appears in the FDA drug-label database. Marketed as TRODELVY.
- Boxed warning
- The FDA label for Sacituzumab govitecan carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated: Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. ( 1.1 , 14.1 ) In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test. ( 1.1 , 14.1 ) Second Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. ( 1.1 , 14.1 ) Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endo…
Phase breakdown
Conditions being studied
Recruiting trials involving Sacituzumab govitecan
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
- Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
- HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan
- Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
- NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
- Organoid-based Functional Precision Therapy for Advanced Breast Cancer
- Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Sacituzumab Govitecan In TNBC
- Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
- Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
- Scalp Cooling in MBC
- Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
- Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
- Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
- Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
Common questions
Is Sacituzumab govitecan FDA-approved?
Yes, marketed as TRODELVY. Its FDA label carries a boxed warning.
How many recruiting trials involve Sacituzumab govitecan?
21 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.